NEtwork to Control ATherothrombosis (NEAT Registry)

Study Overview
=================
Brief Summary
-----------------
NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting.

Detailed Description
-----------------
National multicenter registry in Brazil with initial plan of 25 sites from the 5 Brazilian regions. It will be coordinated by HCOR Research Institute which will perform regulatory, data and site management beyond academic leadership.NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting with 12 months of follow-up with collection of data at baseline, 6 months and 12 months.

Official Title
-----------------
Brazilian Registry of Atherothrombotic Disease

Conditions
-----------------
Coronary Artery Disease, Peripheral Arterial Disease, Atherothrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥45 years followed in ambulatory setting with ≥1 of the following 3 criteria: Documented coronary disease (≥1 criteria must apply): Stable angina History of Unstable Angina History of coronary angioplasty/stenting History of coronary artery bypass graft Myocardial infarction within the last 20 years Documented symptomatic Peripheral Arterial Disease (≥1 criteria must apply): Previous aorto-femoral bypass surgery, limb bypass surgery, or percutaneous transluminal angioplasty revascularization of the iliac, or infra-inguinal arteries, or Previous limb or foot amputation for arterial vascular disease, or History of intermittent claudication and one or more of the following: 1) An ankle/arm blood pressure (BP) ratio < 0.90, or 2) Significant peripheral artery stenosis (≥50%) documented by angiography, or by duplex ultrasound. Exclusion Criteria: Patients from institutions that don't provide the Institutional Authorization Term, Incapacity of follow-up in one year according to investigator judgment (severe neuropsychiatric condition, life expectancy < 12 months)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients receiving evidence based therapies to reduce cardiovascular risk | DOMAIN 1: Appropriate use of antithrombotic therapy | Baseline | 
| Percentage of patients receiving evidence based therapies to reduce cardiovascular risk | DOMAIN 2: Cholesterol control | Baseline | 
| Percentage of patients receiving evidence based therapies to reduce cardiovascular risk | DOMAIN 3: Blood pressure control | Baseline | 
| Percentage of patients receiving evidence based therapies to reduce cardiovascular risk | DOMAIN 4: Glycemic control / diabetes treatment | Baseline | 
| Percentage of patients receiving evidence based therapies to reduce cardiovascular risk | DOMAIN 5: Weight control | Baseline | 
| Percentage of patients receiving evidence based therapies to reduce cardiovascular risk | DOMAIN 6: Non-pharmacological intervention: In this domain, there are 2 items to be evaluated: 1) No smoking; 2) Physical exercise ≥ 150 minutes per week. | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients receiving complete evidence based therapies to reduce cardiovascular risk | Patient should receive all of the following to consider complete evidence based therapy: Appropriate use of antithrombotic therapy; Cholesterol control; Blood pressure control; Glycemic control / diabetes treatment; Weight control; Non-pharmacological intervention | 6 and 12 months | 
| Percentage of patients with complete control of risk factors (blood pressure, cholesterol and glycemia) | blood pressure, cholesterol and glycemia levels at baseline, 06 and 12 months | baseline, 06 and 12 months |